| http://www.w3.org/ns/prov#value | - The annual health and social costs of caring for these patients is estimated to be in excess of ??5 billion in the UK and in excess of US$50 billion in the US. In addition to its stroke programme, ReNeuron is developing stem cell therapies for a number of neurodegenerative diseases and other conditions, including Parkinson???s disease, Type 1 diabetes and diseases of the retina.
|
